PROXIDRUGS

What PROXIDRUGS does

PROXIDRUGS is a federally funded research consortium established in October 2021 under Germany's Clusters4Future initiative, hosted at Goethe University Frankfurt am Main. The cluster operates as a collaborative network of 22 academic and industry partners covering the full drug development value chain from basic research through translational science, focused exclusively on proximity-inducing drugs (proxidrugs) — a novel therapeutic modality that directs disease-relevant proteins toward the cellular recycling system (proteasome/lysosome) for selective degradation. Its technology portfolio spans PROTACs, molecular glues, DARPins, LYTACs, SUMO modification, and first-in-class spliceosome-targeting degraders, organized into ten active research projects including ProxiDETECT, AltTAC, NewPRO, iGLUE, FaMoGLUES, BioDEL, ProxiDIRECT, InnoDATA, ImmunoTUNE, and AntiMIC. Target indications include cancer (notably hepatocellular carcinoma via SpliceTACs and p53 stabilization via AltTAC), neurodegenerative disorders, and infectious diseases.

The cluster has no commercial revenue model. It is funded by the Federal Ministry of Research, Technology and Space (BMFTR), with additional support from Hessen's LOEWE program, House of Pharma, and HTAI. Its go-to-market motion is community-led: research outputs are transferred to industry partners and spin-off companies, and the cluster actively supports technology transfer, spin-off formation, and local partnerships through a dedicated innovation management team. Major industry partners include Merck Healthcare, Merck KGaA, AbbVie, GSK, and Bayer as Steering Board representatives, alongside research-heavy partners such as Max Planck, Fraunhofer ITMP, TU Darmstadt, and the Universities of Frankfurt, Bonn, and Mainz. The cluster does not sell products or services and operates no traditional commercial pricing or distribution channels.

Strategic positioning centers on the premise that approximately 80% of human proteins currently deemed undruggable may be addressable through proximity-inducing drug strategies. Cluster leadership comprises globally recognized scientists including Cluster Speaker Prof. Ivan Đikić and an Advisory Board drawn from the University of Dundee (Ciulli), EPFL (Thomä), and AITHYRA (Winter). The cluster has secured third-party validation through the 2026 Innovation Award of the German BioRegions (SpliceTACs) and the 2026 Kurt Ruths Prize (molecular glues research), and has established transatlantic engagement through the 2026 ProxiUS partnership with UC Berkeley's Molecular Therapeutics Initiative.

Name

PROXIDRUGS

Legal name

Johann Wolfgang Goethe-Universität Frankfurt am Main

Website

https://proxidrugs.de

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

51–100 employees

Short description

PROXIDRUGS is a federally funded German research consortium of 22 academic and industry partners developing proximity-inducing drugs (PROTACs, molecular glues, DARPins) for targeted protein degradation in cancer, neurodegeneration, and infectious diseases.

Ownership category

akta.pro rank

Product category

Drug Discovery Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

akta.pro secondary industries

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• Targeted protein degradation
• Proximity-inducing drugs
• PROTAC development
• Molecular glue discovery
• Drug discovery research

Headquarters

HQ city

Frankfort

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Others

Revenue model

1. Government Research Funding: Funded by the Federal Ministry of Research, Technology and Space (BMFTR) as part of Germany's Clusters4Future initiative since October 2021. The cluster receives federal funding to support collaborative research across 22 academic and industry partners.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

PROXIDRUGS is a federally funded research consortium that develops proximity-inducing drugs (proxidrugs) — including PROTACs, molecular glues, DARPins, LYTACs, and spliceosome-targeting degraders — for targeted protein degradation in diseases with high unmet medical need such as cancer, neurodegenerative disorders, and infectious diseases. It connects 22 academic and industry partners covering the full value chain from basic ubiquitin biology to translational drug discovery, and transfers resulting technologies to pharmaceutical industry partners for further development and commercialization.

Product overview

PROXIDRUGS is a research consortium (Cluster4Future initiative), not a commercial product company. The organization focuses on developing proximity-inducing drugs (proxidrugs) as innovative therapies for human diseases through targeted protein degradation. The portfolio comprises 10 active research projects: ProxiDETECT (molecular glue/degrader identification), AltTAC (alternative targeting approaches including DARPins, SUMO, LYTACs), NewPRO (E3 ligase expansion for PROTACs), iGLUE (molecular glue discovery), FaMoGLUES (FKBP-based molecular glues), BioDEL (in vitro test systems), ProxiDIRECT (cell-specific targeting), InnoDATA (AI/ML data management), ImmunoTUNE (FOXO transcription factor manipulation), and AntiMIC (antibiotic development). Additionally, SpliceTACs represents a first-in-class degrader approach for cancer therapy. The cluster connects 22 academic and industry partners across the entire value chain from basic to translational research.

Differentiator

Problem solved

Functional benefit

Products and services

• ProxiDETECT Research project that refines identification of molecular glues and degraders by combining advanced assay technologies and focused chemical libraries to find E3 ligase binders, profile molecular proximity, and apply innovative imaging to study phenotypic effects of targeted protein degradation.
• AltTAC Research project developing alternative targeting approaches — including DARPins, SUMO modification, and LYTACs — to expand the target space for proximity-inducing drugs, including p53 stabilization for neurodegenerative disorders and other diseases.
• NewPRO Research project that expands the spectrum of E3 ligases and E3 ligase ligands available for PROTAC development, developing novel ligands for new E3 ligases and supporting structural biology and in silico methods for optimization of target-selective PROTACs.
• iGLUE Research project that uses a systematic approach to identify new molecular glues and optimize their pharmacological properties, creating next-generation immuno-modulatory drugs, developing novel cullin ring ligase-dependent degraders, and targeting essential oncogenic proteins.
• FaMoGLUES Research project that develops molecular glues based on adapter proteins of the FKBP class using a leading ligand library, providing proof-of-concept for functional targeting of undruggable cancer targets and validating FaMoGs as a new modality for herbicides.
• BioDEL Research project that develops human in vitro test systems for standardized, predictive high-throughput screening of proxidrugs, focusing on the intestine and blood-brain barrier, with carrier platform technologies and in silico models supporting rational design.
• ProxiDIRECT Research project that develops proxidrugs with cell-specific targeting to expand therapeutic window and reduce non-specific distribution through drug accumulation via intracellular targeting and localization via antibody-drug conjugates.
• InnoDATA Research project that establishes FAIR data management solutions and develops predictive tools utilizing machine learning and artificial intelligence, implementing the legal and structural framework for collaboration and advancing innovation and technology transfer strategy.
• ImmunoTUNE Research project that harnesses expertise in chemical biology, biochemistry, genetics, and immunology to specifically manipulate FOXO transcription factors with cutting-edge proximity-inducing drugs and molecular glues for controlling immunological functions.
• AntiMIC Research project that establishes a development pipeline for highly specific antibiotics based on proximity-inducing compounds, identifying and validating binders to Legionella pneumophila effectors as warheads for PROTACs.
• SpliceTACs First-in-class spliceosome-targeting degraders designed to selectively degrade USP39, a cancer-relevant regulator of spliceosome fidelity, for development of a new therapeutic strategy for advanced hepatocellular carcinoma.

Quantifiable outcome

• 80% of proteins deemed undruggable may be targeted by proximity-inducing drug strategies
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

21 partnerships are on record, tiered core and minor.

• Molecular Therapeutics Initiative at UC BerkeleycoreStrategic or Co-development Partner · 1 January 2026MTI at UC Berkeley is part of the BMFTR-funded ProxiUS project. The transatlantic exchange between PROXIDRUGS and MTI was launched at the PROXIDRUGS-MTI Workshop on Induced Proximity Therapeutics, organized by Ivan Đikić and Michael Rapé.
• AbbVie Deutschland GmbH & Co. KGcoreStrategic or Co-development Partner · 1 October 2021AbbVie is a partner in the PROXIDRUGS consortium, contributing to research projects including AntiDEG for specific degradation of neuronal target proteins and AntiCAN for novel PROTACs in cancer treatment.
• AnalytiCon Discovery – a Division of BRAIN Biotech AGcoreTechnology or Integration · 1 October 2021AnalytiCon Discovery contributes to the consortium with expertise in compound libraries and screening technologies for molecular glue and degrader identification.
• Berliner Institut für Gesundheitsforschung in der Charité (BIH)coreStrategic or Co-development Partner · 1 October 2021BIH at Charité contributes expertise in biomedical research and translation of scientific discoveries into clinical applications.
• CrystalsFirst GmbHcoreTechnology or Integration · 1 October 2021CrystalsFirst contributes structural biology and crystallization expertise for protein structure determination supporting drug design.
• ENAMINE GERMANY GmbHcoreTechnology or Integration · 1 October 2021ENAMINE Germany provides compound libraries and chemical synthesis capabilities for the development of proximity-inducing drugs. They participated in the PROXIDRUGS-MTI Workshop.
• Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.coreStrategic or Co-development Partner · 1 October 2021Fraunhofer ITMP is involved in AntiDEG project for specific degradation of neuronal target proteins and toxic protein aggregates for neurodegenerative diseases. Dr. Aimo Kannt serves as PROXIDRUGS vice-speaker.
• Johann Wolfgang Goethe-Universität FrankfurtcoreStrategic or Co-development Partner · 1 October 2021Goethe University Frankfurt is the host institution for PROXIDRUGS. Prof. Ivan Đikić serves as Cluster Speaker. The university provides the Institute of Biochemistry II as headquarters.
• KRAS Research GmbHcoreStrategic or Co-development Partner · 1 October 2021KRAS Research contributes expertise in KRAS-driven cancer research and drug discovery.
• Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.coreStrategic or Co-development Partner · 1 October 2021Max Planck Institute of Biophysics contributes through Prof. Gerhard Hummer on the Steering Board. The Max Planck Society provides expertise in structural biology and biophysics.
• Merck Healthcare KGaAcoreStrategic or Co-development Partner · 1 October 2021Merck Healthcare is represented on the Steering Board by Dr. Ingo Hartung. Merck contributes to the PROXIDRUGS-MTI Workshop and provides pharmaceutical industry perspective on drug development.
• Merck KGaAcoreStrategic or Co-development Partner · 1 October 2021Merck KGaA (separate from Merck Healthcare) contributes to the consortium with pharmaceutical development expertise and represented by Dr. Charles Seipp on the Steering Board.
• Revvity (Germany) GmbHcoreTechnology or Integration · 1 October 2021Revvity provides assay technologies and screening platforms, represented by Dr. Volker Eckelt on the Steering Board.
• Rheinische Friedrich-Wilhelms-Universität BonncoreStrategic or Co-development Partner · 1 October 2021University of Bonn, represented by Universitätsklinikum Bonn, contributes through Prof. Radosław Nowak on the Steering Board with expertise in targeted protein degraders.
• Technische Universität DarmstadtcoreStrategic or Co-development Partner · 1 October 2021TU Darmstadt hosts the Emanuel Merck Lectureship series and contributes researchers including Prof. Felix Hausch (PROXIDRUGS project leader) who developed molecular glues for targeted cancer therapy.
• Tetra D GmbHcoreTechnology or Integration · 1 October 2021Tetra D contributes computational and AI-based drug discovery tools, represented by Prof. Dr. Petr Popov on the Steering Board.
• Tubulis GmbHcoreStrategic or Co-development Partner · 1 October 2021Tubulis contributes expertise in antibody-drug conjugates and targeted delivery technologies. Dr. Marc-André Kasper represents Tubulis on the Steering Board.
• University Medical Center of Johannes Gutenberg-University Mainz (UMC-Mainz)coreStrategic or Co-development Partner · 1 October 2021UMC-Mainz contributes clinical research capabilities and expertise, represented by Prof. Dr. Daniela Krause on the Steering Board.
• Bayer AGminorStrategic or Co-development Partner · 1 October 2021Bayer AG is an Associated Partner of the PROXIDRUGS consortium, contributing crop science and pharmaceutical development expertise.
• GlaxoSmithKline Research & Development LimitedminorStrategic or Co-development Partner · 1 October 2021GSK is an Associated Partner represented by Dr. Markus Queisser on the Steering Board, contributing pharmaceutical industry perspective.
• House of Pharma & Healthcare e.V.minorStrategic or Co-development Partner · 1 October 2021House of Pharma & Healthcare supports the consortium as an associated partner, providing networking and industry connection services in the Rhine-Main region.

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Arvinas: Clinical-stage biotech pioneering PROTAC-based targeted protein degradation with partnered programs (e.g., vepdegestrant with Pfizer). Directly comparable to PROXIDRUGS as a PROTAC-focused organization.
• Monte Rosa Therapeutics: Clinical-stage biotech developing molecular glue degraders (QuEEN discovery engine) for cancer and immunology. Direct peer in the molecular glue degrader modality that PROXIDRUGS also pursues.
• Nurix Therapeutics: Clinical-stage TPD company using DNA-encoded libraries to identify E3 ligase ligands and develop targeted degraders. Direct peer in ligand discovery and degrader development.
• C4 Therapeutics: Clinical-stage biotech developing small-molecule degraders (TORPEDO platform) for cancer and neurodegenerative diseases. Direct peer in the targeted protein degradation modality.
• Amphista Therapeutics: European TPD biotech developing next-generation targeted protein degraders with a focus on non-CRBN, non-VHL mechanisms. Direct peer and geographic/regional competitor in the TPD space.
• Kymera Therapeutics: Clinical-stage TPD company developing heterobifunctional degraders (PROTACs) and molecular glues across oncology and immunology. Direct peer in proximity-inducing drug development.

Emerging players

• Proteovant Therapeutics: Emerging player focused on targeted protein degradation technologies, spinning out of Roivant. Meaningful overlap with PROXIDRUGS's preclinical degrader programs.
• Foghorn Therapeutics: Clinical-stage biotech applying chromatin biology and protein degradation to oncology targets. Partial overlap with PROXIDRUGS's chromatin/transcription-factor-focused ImmunoTUNE project.

Broad incumbents

• Bristol Myers Squibb: Large pharma incumbent with a major molecular glue degrader franchise (CELMoDs: iberdomide, mezigdomide) and growing PROTAC pipeline. Broad incumbent in the same proximity-inducing drug space.
• Roche: Large incumbent pharma with significant investment in targeted protein degradation, including partnerships and internal LYTAC/AbTAC programs. Comparable as a broad player entering the same modality.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/proxidrugs

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PROXIDRUGS